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Objectives: To estimate the relative ﬁtness differences between glycopeptide-resistant Enterococcus faecium
(GREF) and glycopeptide-susceptible E. faecium (GSEF) from yearly surveillance data on the occurrence of
GREF in Danish poultry farm environments.
Methods: A population genetic model was adapted to retrospectively estimate the biological ﬁtness cost of
acquired resistance. Maximization of a likelihood function was used to predict the longitudinal persistence of
acquired resistance.
Results: Our analysis suggests strong selection against GREF following the 1995 ban on the glycopeptide
growth promoter avoparcin. However, parameterizing the model with two selection coefﬁcients suggesting a
reduced negative effect of the acquired resistance on bacterial ﬁtness over time signiﬁcantly improved the
ﬁt of the model. Our analyses suggest that the acquired glycopeptide resistance will persist for .25 years.
Conclusions: Acquired resistance determinants in commensal E. faecium populations in Danish farm environ-
ments are likely to persist for decades, even in the absence of glycopeptide use.
Keywords: Enterococcus faecium, GREF, Danish
Introduction
Whereas a clear correlation exists between consumption of anti-
biotics and resistance development in microbial communities,
the association between reduced usage and declining frequen-
cies of resistance is less clear.
1,2 Numerous experimental
in vitro and in vivo studies have shown that newly acquired anti-
biotic resistance determinants impose a biological cost on their
bacterial host.
3 Theory predicts that after complete removal of
antibiotic selective pressures, the frequency of resistance will
decline as a function of the magnitude of these biological
costs to the level where mutations or horizontal gene transfer
eventually maintain it.
4 However, validation of this prediction
has been impeded by a lack of documented examples in which
antibiotics have been completely removed from the environ-
ment. Long-term surveillance and analysis of appropriate
empirical data sets are needed to better understand the fate
of antibiotic resistance determinants after removal of positive
directional selection.
5
One example where a type of antibiotic has been completely
removed from the environment concerns Danish and Norwegian
poultry farms following the 1995 ban of the glycopeptide
growth promoter avoparcin, which was used extensively in
animal production in many European countries. Long-term
use of avoparcin had selected for high relative proportions of
vanA-type glycopeptide-resistant enterococci (GRE) in the farm
environment.
6 A ban was imposed because vanA conferred
complete cross-resistance to clinically important glycopeptide
antibiotics such as vancomycin and teicoplanin, considered to
be antibiotics of last resort.
Surveillance data from Denmark demonstrated that the pro-
portions of glycopeptide-resistant E. faecium (GREF) declined
steeply in the ﬁrst 3 years after the ban on avoparcin
(Figure 1).
7 However, the decline seems to have become more
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608moderate in recent years. GREF were still isolated in 2% of the
screened isolates in 2008.
8 The Norwegian surveillance data
are less comprehensive, but the existing data on GREF prevalence
in poultry faeces are consistent with the Danish surveillance
data.
5 Here, we analyse the Danish surveillance data to retro-
spectively investigate this decline and estimate the difference
in relative ﬁtness between GREF and glycopeptide-susceptible
E. faecium (GSEF). These estimates facilitate predictions of
when the current surveillance programme will cease to detect
GREF, and how long it will take for glycopeptide resistance deter-
minants to be lost from the E. faecium population.
Methods
To quantify the biological cost of glycopeptide resistance, we applied a
population genetic model to the available Danish surveillance data,
7,8
under the assumption that the key difference between resistant and sus-
ceptible phenotypes is the presence or absence of horizontally acquired
resistance determinants. The Danish surveillance data are based on non-
selective isolations of E. faecium at slaughter and represent a stratiﬁed
random sample of the respective populations. We assume, since GREF
were obtained in direct non-selective plating assays, that the proportions
of GREF reﬂect the actual proportions in poultry faeces.
8 We estimate the
cost of resistance based on a deterministic, continuous-time, haploid
model of the frequency of resistance in response to selection:
9,10
pt =
p0emt
1−p0+p0emt (1)
where pt is the frequency of resistance at time t, p0 is the frequency of
resistance upon removal of the antibiotic from the environment (i.e. at
the onset of the antibiotic-free period) and m is the continuous-time Mal-
thusian selection coefﬁcient. This model may be ﬁtted to yearly observed
count data on k GREF isolates detected in a sample of size n bya binomial
maximum likelihood function:
L(p0,m)=

t
nt
kt

(pt)kt(1−pt)nt−kt (2)
Results and discussion
Maximizing Equation 2 with a directional selection parameter of
zero (m¼0) yields stasis in GREF frequency and is highly unlikely
(Figure 1). Estimation of a single selection parameter, m, repre-
senting a single Malthusian selection coefﬁcient over the entire
13 year time course, yields a maximum likelihood estimate for
m of 20.44. Converting from continuous to discrete time par-
ameters via m¼ln w yields a discrete-time relative ﬁtness (w)
of w¼0.64. To get an idea of the unit of discrete time (w is
dimensionless) we can further calculate the discrete-time selec-
tion coefﬁcient s of 0.36/year (w¼12s).
11 These data suggest
strong selection against GREF between 1995 and 2008.
However, a closer look at the empirical data in Figure 1
suggests that after a rapid decrease in the frequency of glyco-
peptide resistance between 1995 and 1998, the rate of decline
appears to level out after 1998. The ﬁt of the model is signiﬁ-
cantly improved by parameterizing Equation 1 with two different
continuous-time ﬁtnesses, m1 and m2, where m1 (21.0) applies
for pt from 1995 to 1998 and m2 (20.16) applies for pt from
1998 to 2008 (log likelihood improved from 238.2 to 226.3).
These values of m correspond to discrete-time ﬁtnesses of
w1¼0.37 and w2¼0.85. Because a more gradual change in
population ﬁtness is conceivable, we also ﬁtted the model with
a third selection parameter for the period from 1997 to 1999.
Despite the resulting increase in the number of free parameters,
addition of the third parameter worsened the ﬁt of the model
(log likelihood dropped from 226.3 to 227.4).
The best ﬁt of the two-parameter model (Figure 1) supports a
reduction in the rate of GREF decline after 1998. It also suggests
that the biological cost of carrying glycopeptide resistance deter-
minants was substantially reduced in the E. faecium populations
after a few years. One potential explanation is that the initial
strong selective disadvantage of being glycopeptide resistant
wasmitigatedbycompensatoryevolution.Alternatively,itisposs-
ible that the reduced decline in GREF frequencies may have other
causes, such as linked selection and possibly clonal shifts in the
E. faecium populations.
5 Revealing the proximate causes and
factors resulting in this selection would require a detailed ecologi-
cal/epidemiological model with extensive and poorly known eco-
logical parameters. Since E. faecium is part of the normal ﬂora of
poultryitisreasonabletoassumethatthetotalpopulationisrela-
tivelystableovertime.Asweassumeaconstantoverallpopulation
size,manyecologicalfactors maynot beofdirectrelevancetoour
studyasweareconcernedwiththeeffectofrecentlyacquiredgly-
copeptide resistance in previously susceptible phenotypes. Com-
pensatory adaptation is not assured, and is not amenable to
experimental tests in thegenetically heterogeneousEnterococcus
populations. Despite the inability to dissect additionallycontribut-
ing factors, our likelihood analysis strongly suggests that a signiﬁ-
cant reduction in the cost of glycopeptide-resistant phenotypes
has occurred over a short time period.
The difference in relative ﬁtness between GREF and GSEF
may be associated with the regulated expression of the
Tn1546-encoded vanA operon. Foucault et al.
12 recently demon-
strated that the inactivated or inducible Tn1549-encoded vanB
operon was not costly to the enterococcal host in the absence
of vancomycin. However, while Tn1549 often has a chromosomal
location, Tn1546 is far more frequently located on a genetically
diverse set of large plasmids,
5 and the initial cost of carrying
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Figure 1. Empirical observations of the frequency of GREF in Danish
poultry samples 1995–2008 (ﬁlled circles). Lines show the ﬁt of a
maximum likelihood model to the surveillance data when there is no
selection, a single selection coefﬁcient for the entire time course (m)
and two different selection coefﬁcients (m1 and m2).
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JACacquired vancomycin resistance thus includes carrying the extra-
chromosomal elements.
The maximum likelihood model applied to the Danish surveil-
lance data can further provide realistic estimates of how much
time will pass before GREF will decline to frequencies at which
the current surveillance programme in Denmark would not
successfullyisolateGREFbynon-selectivedirectplating.Moreover,
the time needed for complete loss of resistance in farm animals
canbecalculated(Table1).Extrapolationfromthemodel(assum-
ing a single selection coefﬁcient of m¼20.44) predicts sporadic
detection until 2015, a low probability of detection until 2026
and complete reversal of glycopeptide resistance by 2036.
However, extrapolation based on the better ﬁtting model (with
two selection coefﬁcients and assuming no further drop in the
second, smaller selection coefﬁcient), predicts sporadic detection
until2027,increasinglyreducedprobabilityofdetectionuntil2046
and complete loss of resistance by 2065. These estimates are
helpful but are fairly crude predictions of a potentially complex
outcome. The population genetic model applied here provides
estimates for the waning of GREF relative to GSEF in response to
selection only (i.e. the cost of acquired glycopeptide resistance).
Clonal shifts in the heterogeneous E. faecium populations
(unrelated to glycopeptide resistance carriage) could shorten or
prolong the time. Moreover, ongoing compensatory evolution
might fully restore the ﬁtness of GREF strains and would in that
case prolong the time until reversal of GREF.
With these caveats in mind, it remains clear that whereas the
prevalence of resistance is substantially reduced, and therefore
the goal of lowering the exposure rate to humans of GREF infec-
tions from animal sources may have been met, the long-term
persistence at the single farm animal level entails that reintro-
duction of glycopeptides will lead to a rapid population takeover
by resistant phenotypes.
In conclusion, the presented results suggest that even when
the biological cost of vancomycin resistance is initially high, the
resistance determinants may persist for decades after a com-
plete cessation of glycopeptide consumption in farm animals.
From a clinical perspective, GREF of animal sources are generally
not considered to be nosocomial pathogens at the strain level.
13
However, the long-term persistence of GREF in food animals is
worrying as a reservoir for horizontal transfer of the vanA gene
cluster to clinically relevant enterococcal genetic lineages as
well as to more pathogenic Gram-positive bacteria.
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Table 1. Estimated time for loss of vancomycin resistance in E. faecium
in the normal microbiota of poultry in Denmark
Selection coefﬁcients
Years (from 2010) to reach
a frequency of
a
10
24 10
26 10
28
m (20.44) 5 16 26
m1 (21.0) 1995–98 and
m2 (20.16) 1998–2008
17 36 55
aThe GREF detection limit varies from year to year in DANMAP (Danish
Integrated Antimicrobial resistance Monitoring and Research
Programme) (from 0.09 to 0.005).
7,8 We assume that at a frequency of
10
24 GREF will only rarely be detected and at a frequency of 10
26
GREF will not be detected, and we consider resistance to be lost at a
frequency of 10
28 (prevalence below the enterococcal population per
individual farm animal).
14
Johnsen et al.
610